Skip to Content

Notice

Advisory Committee Renewals; Correction

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice; correction.

SUMMARY:

The Food and Drug Administration (FDA) is correcting a notice entitled “Advisory Committee Renewals” that appeared in the Federal Register of August 25, 2014 (79 FR 50658). The document announced the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs. The table in the document contained several errors. This document corrects those errors.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Lisa Granger, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In the Federal Register of Monday, August 25, 2014, in FR Doc. 2014-20017, on page 50659 the table is corrected to read:

Name of committeeDate of expiration
Advisory Committee for Pharmaceutical Science and Clinical PharmacologyJanuary 22, 2016.
Gastrointestinal Drugs Advisory CommitteeMarch 3, 2016.
Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee)March 23, 2016.
Arthritis Advisory CommitteeApril 5, 2016.
Pharmacy Compounding Advisory CommitteeApril 25, 2016.
Anesthetic and Analgesic Drugs Advisory CommitteeMay 1, 2016.
Blood Products Advisory CommitteeMay 13, 2016.
Pulmonary-Allergy Drugs Advisory CommitteeMay 30, 2016.
Drug Safety and Risk Management Advisory CommitteeMay 31, 2016.
Science Advisory Board to the National Center for Toxicological ResearchJune 2, 2016.
Peripheral and Central Nervous System Drugs Advisory CommitteeJune 4, 2016.
Psychopharmacologic Drugs Advisory CommitteeJune 4, 2016.
Transmissible and Spongiform Encephalopathies Advisory CommitteeJune 9, 2016.
Science Board to the Food and Drug AdministrationJune 26, 2016.
Allergenic Products Advisory CommitteeJuly 9, 2016.
Start Signature

Dated: September 3, 2014.

Jill Hartzler Warner,

Associate Commissioner for Special Medical Programs.

End Signature End Supplemental Information

[FR Doc. 2014-21369 Filed 9-8-14; 8:45 am]

BILLING CODE 4164-01-P